[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rosacea-erythematotelangiectatic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rosacea-erythematotelangiectatic":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100638035","transcutaneous-auricular-vagus-nerve-stimulation-treatment-for-rosacea-100638035",false,"NCT07600424","Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea","Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea: A Pilot Trial","Inclusion Criteria:\n\n* Adults aged 18 years of age and older\n* Dermatologist confirmed diagnosis of rosacea\n* Clinician's Erythema Assessment of at least 3 (moderate to severe disease)\n* Willingness to adhere to current rosacea regimen without additions or laser treatments (e.g. PDL) during the study period.\n\nExclusion Criteria:\n\n* Changes to rosacea regimen (prescription topical or oral medications) within 4 weeks of randomization.\n* Facial hair, tattoos, or other characteristics that would interfere with erythema assessments\n* History of symptomatic cardiac arrythmias (e.g. heart block, sick sinus syndrome, bradyarrhythmia)\n* Presence of a pacemaker, implanted defibrillator, or neurostimulator\n* Seizure disorder or epilepsy\n* Trigeminal Neuralgia within the past year\n* Severe coronary disease or recent myocardial infarction within the past 5 years\n* Severe autonomic dysfunction (e.g., frequent syncope, hospitalization)\n* History of recurrent syncope or unexplained fainting\n* Use of brimonidine or oxymetazoline within the past 4 weeks\n* Use of beta-blockers, anticholinergics, or vagal-modulating drugs within the past 4 weeks\n* Severe phymatous rosacea\n* Ear deformity, piercings, or other condition that prevents the use of the taVNS device\n* Known hypersensitivity to electrode materials\n* Patients who are pregnant.","ALL","18 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"NA","A single arm, pilot study among individuals with rosacea and at least moderate flushing or rednesss will be enrolled in a 4-week trial of taVNS. The particicpants will be followed for an additional 4-weeks following the intervention period to evaluate the durability of the results",[26,27,28],"Rosacea","Rosacea, Erythematotelangiectatic","Flushing","NOT_YET_RECRUITING","2026-05-20",{"date":32,"type":33},"2026-05-22","ACTUAL",{"date":35,"type":20},"2026-06-01",{"date":37,"type":20},"2028-02-28",{"name":39,"class":40},"Brigham and Women's Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100633036","dermocosmetic-treatment-for-facial-redness-in-rosacea-with-or-without-laser-therapy-100633036","NCT07521462","Dermocosmetic Treatment for Facial Redness in Rosacea With or Without Laser Therapy","Impact of Using a Dermocosmetic Product as Monotherapy or as an Adjunct to Laser Treatment on Redness Associated With Erythematotelangiectatic Rosacea: a Comparative Study Versus Placebo.","Inclusion Criteria:\n\n* Gender: male or female\n* Age: \\> 18 years -Patients with mild to severe erythro-couperotic rosacea (stage 2, 3, or 4 - TRoSA scale, section 2.2.3.1)\n* Patients wishing to undergo vascular laser treatments for their rosacea\n* Patients who have provided informed consent\n\nExclusion Criteria:\n\n* Pregnant patients or patients with a positive urine pregnancy test at the initial visit\n* Patients with another condition in the study area.\n* Patients who have received laser treatment for the same condition within the previous 12 months.\n* Patients with another form of rosacea (e.g., papules and pustules, ocular rosacea, etc.).\n* Patients using another anti-redness product on the face during the study.\n* Patients who have taken photosensitizing treatments during the month prior to study enrollment.\n* Patients taking or having taken oral isotretinoin within 6 months prior to study enrollment.\n* Patients enrolled in another study.\n* Adult patients under a legal guardianship arrangement (guardianship, conservatorship, judicial protection).\n* Patients not covered by social security.",{"count":50,"type":20},50,[23],"The aim of this clinical study is to evaluate the effectiveness and safety of a dermocosmetic product in reducing facial redness and visible blood vessels associated with erythematotelangiectatic rosacea.\n\nInvestigators will compare the dermocosmetic product to a placebo applied to opposite sides of the face, when used alone and in combination with laser treatment.\n\nParticipants will apply the products twice daily for 2 month followed by continued use in combination with laser treatment, and will attend regular clinical visits for assessments and questionnaires.",[27,54],"Rosacea Subtype 1 (Erythematotelangiectatic)",[56,57,58,59],"Erythematotelangiectatic Rosacea","Telangiectasia","Dermocosmetic","Laser Therapy","2026-04-03",{"date":62,"type":33},"2026-04-13",{"date":64,"type":20},"2026-09-01",{"date":66,"type":20},"2027-06-30",{"name":68,"class":69},"ISISPHARMA","INDUSTRY",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":41},"100577701","rosacea-radiofrequency-microneedling-100577701","NCT06801717","Rosacea Radiofrequency Microneedling","Split-Face Comparison of 532nm Potassium Titanyl Phosphate (KTP) Laser Treatment Versus Radiofrequency Microneedling in Combination With 532 KTP Laser for Erythematotelangiectatic or Papulopustular Rosacea","Inclusion Criteria:\n\n1. Male or female adult (\\>18yo) subjects in general good health\n2. Clinical and\u002For histologic diagnosis of erythematotelangiectatic or papulopustular rosacea.\n3. Subject is able to understand and sign informed consent\n4. Subject is able to complete the study and comply with study procedures\n\nExclusion Criteria:\n\n1. Patients currently utilizing oxymetazoline or brimonidine.\n2. Presence of dermatoses that might interfere with diagnosis as determined by a study investigator\n3. Presence of extreme light sensitivity, or conditions pre-disposing to light sensitivity such as but not limited to xeroderma pigmentosum\n4. Any significant medical condition that may prevent the patient from participating in the study according to the investigator's assessment\n5. History of poor wound healing or blood-clotting abnormality\n6. History of keloid formation or hypertrophic scarring\n7. Hypersensitivity or contraindication to local anesthetics as determined by the principal investigator or other medical professional.\n8. Prisoners",{"count":78,"type":20},20,[23],"There are 3 main objectives of this proposal as follows: (1) to assess the efficacy of radiofrequency microneedling in the treatment of erythematotelangiectatic and or papulopustular rosacea, (2) to determine the potential for combination treatment of radiofrequency microneedling with the 532 nm KTP laser, and (3) identify potential novel therapeutic strategies for the treatment of rosacea.",[82,27],"Rosacea, Papulopustular","RECRUITING","2026-04-02",{"date":86,"type":33},"2026-04-08",{"date":88,"type":33},"2024-11-01",{"date":90,"type":20},"2026-07-01",{"name":92,"class":40},"University of Miami"]